The Swiss National Bank has decreased its holdings in shares of Axon Enterprise, Inc by 3.2% during the third quarter of 2023. According to a recent filing with the Securities and Exchange Commission (SEC), the bank now owns 213,200 shares of the biotechnology company after selling 7,100 shares during this period. This reduction means that the Swiss National Bank holds approximately 0.27% of Axon Enterprise, valued at $153 million.
Several other institutional investors have also made notable moves regarding Axon’s stock. Vanguard Group Inc. increased its position in Axon by 4.2%, acquiring an additional 376,904 shares, bringing its total holdings to 9,314,164 shares, valued at approximately $6.68 billion. Similarly, Geode Capital Management LLC grew its stake by 5.9%, now holding 2,072,186 shares worth around $1.71 billion after purchasing an additional 115,349 shares.
In a striking move, Jennison Associates LLC increased its holdings by 53.8% in the third quarter, now owning 943,944 shares valued at $677 million. Additionally, Vestor Capital LLC has significantly boosted its position by 438,636.3%, acquiring 833,599 shares worth about $690 million. Another major player, Norges Bank, initiated a new stake in Axon valued at approximately $637.81 million. Collectively, hedge funds and other institutional investors own 79.08% of Axon’s stock.
Insider Transactions and Stock Performance
In related news, insider trading activities have also been notable. On March 2, 2024, Jennifer H. Mak, Chief Accounting Officer, sold 1,500 shares at an average price of $573.45, totaling $860,175. Following this transaction, her ownership decreased by 10.92% to 12,240 shares valued at approximately $7 million. On December 11, 2023, Brittany Bagley, Chief Financial Officer, sold 2,000 shares for a total of $1.16 million, resulting in a 1.90% decrease in her holdings to 103,501 shares valued at around $60 million.
In total, insiders have sold 26,634 shares valued at approximately $14.96 million in the last 90 days, with company insiders owning 5.70% of the company’s stock.
Axon’s stock experienced a decline of 2.6%, opening at $559.06 on Tuesday. The company has a 50-day simple moving average of $535.65 and a 200-day simple moving average of $615.42. Over the past year, Axon’s shares have fluctuated between a 52-week low of $396.41 and a 52-week high of $885.91. The company holds a market capitalization of approximately $44.95 billion, with a price-to-earnings ratio of 367.81 and a debt-to-equity ratio of 0.53.
Financial Performance and Future Outlook
Axon Enterprise published its most recent quarterly earnings on February 24, 2024, reporting earnings of $2.15 per share, surpassing the consensus estimate of $1.60 by $0.55. The firm generated $796.72 million in revenue for the quarter, exceeding analyst predictions of $755.29 million. This performance reflects a year-over-year revenue growth of 38.5%, with last year’s earnings per share at $2.08. Analysts anticipate that Axon Enterprise will achieve an average earnings per share of $5.80 for the current fiscal year.
Axon Enterprise, Inc. develops technology and weapons systems tailored for public safety and law enforcement agencies. Its product offerings include conducted energy weapons, commonly known as TASER devices, body-worn cameras, and in-car camera systems. The company integrates these devices with a suite of software solutions for digital evidence management, evidence review, and records management, ensuring a comprehensive approach to modern law enforcement needs.
With these developments, stakeholders will be closely monitoring Axon’s financial trajectory and market position as it navigates the complexities of the evolving biotechnology landscape.
